Product
Birinapant
2 clinical trials
11 indications
Indication
Solid TumorIndication
Colorectal CancerIndication
Non-Hodgkin LymphomaIndication
SarcomaIndication
ChondrosarcomaIndication
Small Lymphocytic LymphomaIndication
Chronic Lymphocytic LeukemiaIndication
Acute Myeloid LeukemiaIndication
Head and Neck Squamous Cell CarcinomaIndication
Nasopharyngeal Squamous Cell CarcinomaClinical trial
An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) as a Single Agent and in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed CancersStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Status: Terminated, Estimated PCD: 2023-11-15